Early bird
tickets
available now!
NEWS
Unexpected benefits of weight loss drugs revealed
POSTED 18 Jun 2024 . BY Kath Hudson
Weight-loss drugs can help with mental health Credit: Mohammed_Al_Ali
Studies show GLP-1 drugs have benefits beyond weight loss
They can be used to treat mental health, addictions, some eating disorders and neurodegeneration
As well as suppressing appetite, it appears they can also suppress addictive cravings
Neuroinflammation is dampened down and cognition and emotional processing areas of the brain stimulated
According to a number of recent studies, semaglutide weight-loss drugs can be effective in treating depression, anxiety, dementia, addiction and some eating disorders.

There is a great deal of research, and more ongoing, which shows the broad-ranging benefits of weight loss drugs, which could potentially lead to them being prescribed for a range of illnesses in the future.

The drugs work for weight loss by mimicking the hormone, glucagon-like peptide-1 (GLP-1), which is produced by the gut and brain, and leads to an increased feeling of satiety. As GLP-1 receptors are peppered throughout the brain – including areas important for cognitive functions and emotional control, such as the prefrontal cortex, hippocampus and amygdala – research shows that stimulating these receptors could be beneficial for other health issues too.

Rodrigo Mansur, from the University of Toronto, led a small study giving liraglutide to 19 people with major depressive disorder or bipolar disorder and within a month they reported better mood, attention span and cognitive function. MRI scans of the participants’ brains revealed that the areas involved in planning, organisation and emotional processing significantly increased in volume within a month. Mansur is now conducting a randomised controlled trial to investigate the ability of GLP-1 drugs to directly treat mood disorders.

GLP-1 has also been shown to increase the brain’s blood flow, slow down the death of nerve cells and promote the flow of glucose to the brain, which is an incredibly sugar-hungry organ, consuming up to 20 per cent of calories. Some studies show that GLP-1 modulates the transport of glucose across the blood-brain barrier, slows the rate at which the brain consumes glucose, reduces oxidative stress and damps down inflammation, which leads to cardiovascular benefits.

Some studies have shown benefits of treating brain diseases, such as Parkinson’s and Alzheimer’s, which are characterised by neuroinflammation. Pharmaceutical company, Novo Nordisk, is currently working on two trials testing semaglutide for Alzheimer’s disease. There is hope these drugs could also help other brain conditions, such as epilepsy and stroke.

A study at Penn State Neuroscience Institute used anti-obesity drugs to treat opioid addiction and found a 40 per cent reduction in opioid cravings over three weeks compared with those receiving a placebo. Researchers suspect the drugs target addiction in a similar way to hunger drive, by influencing the two areas of the brain involved with reward processing and cravings. A larger trial is now underway.

Last year, University of Oklahoma found that semaglutide was more effective in helping people with binge eating disorder than the only medication currently approved by the US Food and Drug Administration (FDA) for this condition. Other evidence suggests that GLP-1s might also help treat bulimia nervosa, an eating disorder which presents as bingeing and purging.

However, there are a few snags with what appears to be a wonder drug. Widespread use of weight-loss medication might lead to further idealisation of slim bodies. It is not yet known if people who aren’t overweight can take GLP-1s safely for mental health reasons alone, as reducing their appetite could lead to malnourishment or becoming critically underweight. For this reason they are not suitable for people suffering from the eating disorder, anorexia nervosa, even though it often stems from anxiety and is an addiction to restricting food.

The research studies have been published in New Scientist magazine.



 


CONTACT US

Leisure Media
Tel: +44 (0)1462 431385

©Cybertrek 2024

ABOUT LEISURE MEDIA
LEISURE MEDIA MAGAZINES
LEISURE MEDIA HANDBOOKS
LEISURE MEDIA WEBSITES
LEISURE MEDIA PRODUCT SEARCH
PRINT SUBSCRIPTIONS
FREE DIGITAL SUBSCRIPTIONS
 
Leisure Management - Unexpected benefits of weight loss drugs revealed...
17 Jul 2024 Leisure Management: daily news and jobs
 
 
HOME
JOBS
NEWS
FEATURES
PRODUCTS
FREE DIGITAL SUBSCRIPTION
PRINT SUBSCRIPTION
ADVERTISE
CONTACT US
Sign up for FREE ezine
Latest news

18 Jun 2024

Unexpected benefits of weight loss drugs revealed
BY Kath Hudson

Weight-loss drugs can help with mental health

Weight-loss drugs can help with mental health
photo: Mohammed_Al_Ali

According to a number of recent studies, semaglutide weight-loss drugs can be effective in treating depression, anxiety, dementia, addiction and some eating disorders.

There is a great deal of research, and more ongoing, which shows the broad-ranging benefits of weight loss drugs, which could potentially lead to them being prescribed for a range of illnesses in the future.

The drugs work for weight loss by mimicking the hormone, glucagon-like peptide-1 (GLP-1), which is produced by the gut and brain, and leads to an increased feeling of satiety. As GLP-1 receptors are peppered throughout the brain – including areas important for cognitive functions and emotional control, such as the prefrontal cortex, hippocampus and amygdala – research shows that stimulating these receptors could be beneficial for other health issues too.

Rodrigo Mansur, from the University of Toronto, led a small study giving liraglutide to 19 people with major depressive disorder or bipolar disorder and within a month they reported better mood, attention span and cognitive function. MRI scans of the participants’ brains revealed that the areas involved in planning, organisation and emotional processing significantly increased in volume within a month. Mansur is now conducting a randomised controlled trial to investigate the ability of GLP-1 drugs to directly treat mood disorders.

GLP-1 has also been shown to increase the brain’s blood flow, slow down the death of nerve cells and promote the flow of glucose to the brain, which is an incredibly sugar-hungry organ, consuming up to 20 per cent of calories. Some studies show that GLP-1 modulates the transport of glucose across the blood-brain barrier, slows the rate at which the brain consumes glucose, reduces oxidative stress and damps down inflammation, which leads to cardiovascular benefits.

Some studies have shown benefits of treating brain diseases, such as Parkinson’s and Alzheimer’s, which are characterised by neuroinflammation. Pharmaceutical company, Novo Nordisk, is currently working on two trials testing semaglutide for Alzheimer’s disease. There is hope these drugs could also help other brain conditions, such as epilepsy and stroke.

A study at Penn State Neuroscience Institute used anti-obesity drugs to treat opioid addiction and found a 40 per cent reduction in opioid cravings over three weeks compared with those receiving a placebo. Researchers suspect the drugs target addiction in a similar way to hunger drive, by influencing the two areas of the brain involved with reward processing and cravings. A larger trial is now underway.

Last year, University of Oklahoma found that semaglutide was more effective in helping people with binge eating disorder than the only medication currently approved by the US Food and Drug Administration (FDA) for this condition. Other evidence suggests that GLP-1s might also help treat bulimia nervosa, an eating disorder which presents as bingeing and purging.

However, there are a few snags with what appears to be a wonder drug. Widespread use of weight-loss medication might lead to further idealisation of slim bodies. It is not yet known if people who aren’t overweight can take GLP-1s safely for mental health reasons alone, as reducing their appetite could lead to malnourishment or becoming critically underweight. For this reason they are not suitable for people suffering from the eating disorder, anorexia nervosa, even though it often stems from anxiety and is an addiction to restricting food.

The research studies have been published in New Scientist magazine.






Connect with
Leisure Management
Magazine:
View issue contents
Sign up:
Instant Alerts/zines

Print edition
 

News headlines
All systems go for GoJoe app with Les Mills partnership, investment and campaigns
All systems go for GoJoe app with Les Mills partnership, investment and campaigns   16 Jul 2024

Employee wellness app GoJoe has teamed up with Les Mills for a major new content offering, giving access to hundreds of new workouts. The .... more>>
Accessible health for all drives David Beckham to co-found health and wellness brand
Accessible health for all drives David Beckham to co-found health and wellness brand   16 Jul 2024

Former footballer, David Beckham, has become a strategic investor in health sciences company, Prenetics, which pioneers scientific advancements in .... more>>
Rianna Riego joins Seed to Skin as director of global business development
Rianna Riego joins Seed to Skin as director of global business development   15 Jul 2024

Rianna Riego, a seasoned professional in the wellness and spa industry, has been appointed director of global business development at Seed to Skin .... more>>
Mindbody adds bespoke insurance to its list of offerings
Mindbody adds bespoke insurance to its list of offerings   12 Jul 2024

Mindbody, has launched a specialist insurance programme for its customers which is being delivered through its platform. Organised in partnership .... more>>
LifeFit Group is rolling out Club Pilates across Germany, ahead of Austria and the Netherlands
LifeFit Group is rolling out Club Pilates across Germany, ahead of Austria and the Netherlands   12 Jul 2024

After introducing Xponential’s reformer Pilates concept, Club Pilates, to Germany last year, Matin Seibold's LifeFit Group reports that it's .... more>>
Study shows major differences in the way males and females burn fat during exercise
Study shows major differences in the way males and females burn fat during exercise   10 Jul 2024

The way fat stores are metabolised during exercise is different in males and females, according to a US study, which shows the need for more research .... more>>
Company profile


Spivi

Spivi is an immersive fitness gamification platform that helps gym operators to achieve better retention by utilizing existing wearables, equipment, and sensors in the club.

View full profile>>

Catalogue gallery


Featured Supplier

THFI’s new online coaching course partners with FITR: launch your business confidently post-completion

THFI’s new online coaching course partners with FITR: launch your business confidently post-completion

In today's rapidly evolving fitness industry, where many online courses promise secret formulas for entrepreneurial success, the reality is that few provide the necessary knowledge to thrive in this fast-changing profession. More>>




in this issue

• Virgin gets right to wipe out rent arrears
• Fitness industry mourns passing of Jan Spaticchia
• STA offers mindfulness resources



Latest jobs

Jobs Search



Facility Manager - LSBU Active
Salary: £31,396 to £34,557, inclusive of £4,952 London Weighting
Location: London, UK
Company: London South Bank University
Exercise Referral Instructor
Salary: Competitive
Location: Hornchurch
Company: Everyone Active
Duty Manager (Dry)
Salary: Competitive salary
Location: St Albans, UK
Company: Everyone Active
Diary dates
Powered by leisurediary.com

17-17 Jul 2024

UK Spa Association - Summer networking event

Pennyhill Park , Bagshot, United Kingdom







Published by Leisure Media Tel: +44 (0)1462 431385 | Contact us | About us | © Cybertrek Ltd